$120 million Series B funding to Pelsge Research/Science 10/15/2025
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
View this post in the Community →
Similar Community Posts Join
5 / 41 resultscommunity The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
community Will Pp405 be the Ozempic of bald Guys
PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.
community How Veradermics secured a total of $220 million in series B and C financing for oral minoxidil, I will never understand.....
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.
community Pelage receiving over $100 million from investors doesn't always equal success.
Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
Related Research
6 / 14 results
research Classified Advertising
The document listed various medical job opportunities with competitive benefits and living conditions.
research A Review of Hand-Held, Home-Use Cosmetic Laser and Light Devices
Home-use cosmetic laser and light devices show modest results for hair removal and acne treatment, but more research is needed for confirmation.
research Platelet-Rich Plasma for Hair Loss
Platelet-Rich Plasma (PRP), a protein-rich extract from a patient's blood, shows promise in improving hair density, thickness, and quality, but the best method of use and number of treatments needed for noticeable results are still unclear.
research How Much Health Insurance Is Enough? Revisiting the Concept of Underinsurance
The document concludes that there is no clear definition of adequate health insurance, and a consistent method to measure underinsurance is needed.
research Skin and Hair: Models for Exploring Organ Regeneration
Skin and hair can help us understand organ regeneration, especially how certain stem cells might be used to form new organs.
research Therapeutic Applications and Pharmacoeconomics of Microneedle Technology
Microneedle technology is beneficial for drug delivery and could make vaccinations cheaper and more accessible.